ArticleAmerican journal of epidemiology2024
Considerations for Use of Blood-Based Biomarkers in Epidemiologic Dementia Research.
Article in American journal of epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer's Disease Continuum: A Systematic Review.Neuropsychology review · 2026Pooled it
- Probing effect modification by socioeconomic status in associations between blood biomarkers of neuropathology and cognitive outcomes in the United States and India.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Bacillus Calmette-Guérin (BCG) Vaccination and the Immune-Brain Axis: Implications for Neuroprotection and Neurodegenerative Disease.Vaccines · 2026Review
- Substituting blood-based biomarkers for imaging measures in Alzheimer's disease studies: implications for sample size and bias.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Cross-sectional associations between lifecourse dementia risk factors, plasma neurodegenerative biomarkers, and cognition in older adults in India.Journal of Alzheimer's disease : JAD · 2026Article
- Substituting Blood-Based Biomarkers for Imaging Measures in Alzheimer's Disease Studies: Implications for Sample Size and Bias.medRxiv : the preprint server for health sciences · 2025Article
- Cross-sectional associations between lifecourse dementia risk factors, plasma neurodegenerative biomarkers, and cognition in older adults in India.medRxiv : the preprint server for health sciences · 2025Article
- Associations between blood-based neurodegenerative biomarkers and cognitive functioning and decline in India.Journal of Alzheimer's disease : JAD · 2025Article
- Investigating the role of chronic stress and perceived discrimination in racial disparities in incident dementia among U.S. older adults.Social science & medicine (1982) · 2025Article
- Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study.Journal of the National Cancer Institute · 2024Article
- Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.Neurology · 2024Article
- Willing, but unequally: Indigenous identity influences participation in Alzheimer's disease biomarker research in Chile.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Dementia represents a growing public health burden with large social, racial, and ethnic disparities. The etiology of dementia is poorly understood, and the lack of robust biomarkers in diverse, population-representative samples is a barrier to moving dementia research forward. Existing biomarkers and other measures of pathology-derived from neuropathology, neuroimaging, and cerebrospinal fluid samples-are commonly collected from predominantly White and highly educated samples drawn from academic medical centers in urban settings. Blood-based biomarkers are noninvasive and less expensive, offering promise to expand our understanding of the pathophysiology of dementia, including in participants from historically excluded groups. Although largely not yet approved by the Food and Drug Administration or used in clinical settings, blood-based biomarkers are increasingly included in epidemiologic studies on dementia. Blood-based biomarkers in epidemiologic research may allow the field to more accurately understand the multifactorial etiology and sequence of events that characterize dementia-related pathophysiological changes. As blood-based dementia biomarkers continue to be developed and incorporated into research and practice, we outline considerations for using them in dementia epidemiology, and illustrate key concepts with Alzheimer's Disease Neuroimaging Initiative (2003-present) data. We focus on measurement, including both validity and reliability, and on the use of dementia blood-based biomarkers to promote equity in dementia research and cognitive aging. This article is part of a Special Collection on Mental Health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.